Start › Szpiczak mnogi › Kalifornia › Los Angeles
Badania kliniczne dla Szpiczak mnogi w mieście Los Angeles, CA
17 badań dla Szpiczak mnogi szuka uczestników w ośrodkach w mieście Los Angeles i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RekrutacjaFaza 3
- Valkyrie Clinical Trials, Los Angeles
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
RekrutacjaFaza 4
- Berenson Cancer Center, Los Angeles
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RekrutacjaFaza 3
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RekrutacjaFaza 3
- Valkyrie Clinical Trials, Los Angeles
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
RekrutacjaFaza 2/3
- Cedars-Sinai Medical Center /ID# 278238, Los Angeles
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekrutacjaFaza 2
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
RekrutacjaFaza 3
- UCLA Hematology/Oncology - Santa Monica, Los Angeles
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekrutacjaFaza 2
- UCLA Hematology/Oncology - Westwood (Building 200 Suite 214), Los Angeles
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RekrutacjaFaza 1/2
- University of Southern California /ID# 272414, Los Angeles
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RekrutacjaFaza 3
- Clinical Research Advisors (Korea Town Satellite Location), Los Angeles
- Clinical Research Advisors (West Hollywood Satellite Location), Los Angeles
- Valkyrie Clinical Trials, Los Angeles
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RekrutacjaFaza 1/2
- GSK Investigational Site, Los Angeles
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RekrutacjaFaza 1/2
- Research Site, Los Angeles
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
RekrutacjaFaza 1
- Cedars-Sinai Medical Center, Los Angeles
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Rekrutacja
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- Cedars Sinai Medical Center, Los Angeles
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RekrutacjaFaza 3
- UCLA Medical Center, Los Angeles
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
RekrutacjaFaza 1/2
- University of California Los Angeles (UCLA), Los Angeles
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
RekrutacjaFaza 1/2
- Valkyrie Clinical Trials, Los Angeles
Badania dla Szpiczak mnogi w innych miastach
- New York City, NY60 badań
- Boston, MA42 badań
- Atlanta, GA41 badań
- Houston, TX38 badań
- Durham, NC37 badań
- Nashville, TN32 badań
- Denver, CO27 badań
- Rochester, MN24 badań
- St. Louis, MO24 badań
- Columbus, OH24 badań
- Baldwin Park, CA23 badań
- Chicago, IL22 badań
Inne badania w mieście Los Angeles
- Niedrobnokomórkowy rak płuca87 badań
- Nowotwory (wszystkie typy)73 badań
- Rak piersi72 badań
- Rak prostaty61 badań
- Rak jelita grubego i odbytnicy59 badań
- Nowotwór przerzutowy57 badań
- Rak jajnika50 badań
- Rak płuc45 badań
- Rak płaskonabłonkowy głowy i szyi42 badań
- Rak trzustki35 badań
- Rak endometrium34 badań
- Czerniak34 badań
Źródło: ClinicalTrials.gov, dane pobrane 5 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.